secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001493152-23-006339
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals appoints David Krempa as Chief Business Officer
--------------------------------------------------------------------

- Effective March 1, 2023, David Krempa promoted from SVP Business Development & IR to Chief Business Officer.
- Annual salary of $385,000; eligible for discretionary annual bonus and participates in 2018 Equity Incentive Plan.
- Severance: 6 months base salary if terminated without cause or for good reason; accelerated vesting on change-in-control within 12 months.
- Krempa has been with Eton since 2017, previously serving as SVP, VP, and Executive Director of Business Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223006339/0001493152-23-006339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223006339/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer